| Ticker | Status | Jurisdiction | Filing Date | CP Start | CP End | CP Loss | Deadline |
|---|
| Ticker | Case Name | Status | CP Start | CP End | Deadline | Settlement Amt |
|---|
| Ticker | Name | Date | Analyst Firm | Up/Down | Target ($) | Rating Change | Rating Current |
|---|
In the ever-evolving and intensely competitive business landscape, conducting a thorough company analysis is of utmost importance for investors and industry followers. In this article, we will carry out an in-depth industry comparison, assessing Merck & Co (NYSE:MRK) alongside its primary competitors in the Pharmaceuticals industry. By meticulously examining key financial metrics, market positioning, and growth prospects, we aim to offer valuable insights to investors and shed light on company's performance within the industry.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent pediatric diseases as well as human papillomavirus, or HPV. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the company's sales are generated in the United States.
| Company | P/E | P/B | P/S | ROE | EBITDA (in billions) | Gross Profit (in billions) | Revenue Growth |
|---|---|---|---|---|---|---|---|
| Merck & Co Inc | 141.67 | 8 | 5.29 | 12.22% | $6.96 | $12.23 | 8.89% |
| Eli Lilly and Co | 130.34 | 65.65 | 22.25 | 19.02% | $3.12 | $7.09 | 25.98% |
| Novo Nordisk A/S | 48.98 | 43.91 | 17.90 | 24.73% | $36.91 | $55.43 | 22.45% |
| Johnson & Johnson | 21.69 | 5.02 | 4.29 | 4.69% | $5.68 | $14.87 | 2.34% |
| AstraZeneca PLC | 39.17 | 6.57 | 5.20 | 5.69% | $4.47 | $10.46 | 16.55% |
| Novartis AG | 23.85 | 5.40 | 4.56 | 6.23% | $4.66 | $9.02 | 9.71% |
| GSK PLC | 14.75 | 4.73 | 2.15 | 7.69% | $2.07 | $5.39 | 5.93% |
| Zoetis Inc | 32.93 | 15.42 | 9.02 | 11.91% | $0.93 | $1.55 | 9.5% |
| Takeda Pharmaceutical Co Ltd | 45.49 | 0.89 | 1.54 | -0.04% | $186.41 | $668.37 | -5.43% |
| Dr Reddy's Laboratories Ltd | 17.93 | 3.55 | 3.58 | 4.77% | $20.32 | $41.48 | 12.49% |
| Jazz Pharmaceuticals PLC | 23.71 | 1.95 | 2.06 | -0.39% | $0.23 | $0.81 | 1.03% |
| Prestige Consumer Healthcare Inc | 15.55 | 1.96 | 2.89 | 3.04% | $0.09 | $0.15 | -3.11% |
| Corcept Therapeutics Inc | 27.23 | 5.43 | 6.03 | 5.22% | $0.03 | $0.14 | 38.95% |
| Average | 36.8 | 13.37 | 6.79 | 7.71% | $22.08 | $67.9 | 11.37% |
By closely studying Merck & Co, we can observe the following trends:
The current Price to Earnings ratio of 141.67 is 3.85x higher than the industry average, indicating the stock is priced at a premium level according to the market sentiment.
The current Price to Book ratio of 8.0, which is 0.6x the industry average, is substantially lower than the industry average, indicating potential undervaluation.
With a relatively low Price to Sales ratio of 5.29, which is 0.78x the industry average, the stock might be considered undervalued based on sales performance.
The company has a higher Return on Equity (ROE) of 12.22%, which is 4.51% above the industry average. This suggests efficient use of equity to generate profits and demonstrates profitability and growth potential.
Compared to its industry, the company has lower Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) of $6.96 Billion, which is 0.32x below the industry average, potentially indicating lower profitability or financial challenges.
The company has lower gross profit of $12.23 Billion, which indicates 0.18x below the industry average. This potentially indicates lower revenue after accounting for production costs.
With a revenue growth of 8.89%, which is much lower than the industry average of 11.37%, the company is experiencing a notable slowdown in sales expansion.
The debt-to-equity (D/E) ratio gauges the extent to which a company has financed its operations through debt relative to equity.
Considering the debt-to-equity ratio in industry comparisons allows for a concise evaluation of a company's financial health and risk profile, aiding in informed decision-making.
In light of the Debt-to-Equity ratio, a comparison between Merck & Co and its top 4 peers reveals the following information:
Merck & Co has a stronger financial position compared to its top 4 peers, as evidenced by its lower debt-to-equity ratio of 0.85.
This suggests that the company has a more favorable balance between debt and equity, which can be perceived as a positive indicator by investors.
For Merck & Co in the Pharmaceuticals industry, the PE ratio is high compared to peers, indicating potential overvaluation. The PB ratio is low, suggesting undervaluation relative to industry standards. The PS ratio is also low, signaling a possible undervalued position. In terms of ROE, Merck & Co shows a high return on equity, outperforming industry peers. However, EBITDA, gross profit, and revenue growth are all low, indicating weaker operational performance compared to competitors.
This article was generated by Benzinga's automated content engine and reviewed by an editor.
Posted In: MRK
